Abstract

Background

Clinical metagenomics (CMg) has the potential to be translated from a research tool into routine service to improve antimicrobial treatment and infection control decisions. The SARS-CoV-2 pandemic provides added impetus to realise these benefits, given the increased risk of secondary infection and nosocomial transmission of multi-drug-resistant (MDR) pathogens linked with the expansion of critical care capacity.

Methods

CMg using nanopore sequencing was evaluated in a proof-of-concept study on 43 respiratory samples from 34 intubated patients across seven intensive care units (ICUs) over a 9-week period during the first COVID-19 pandemic wave.

Results

An 8-h CMg workflow was 92% sensitive (95% CI, 75–99%) and 82% specific (95% CI, 57–96%) for bacterial identification based on culture-positive and culture-negative samples, respectively. CMg sequencing reported the presence or absence of β-lactam-resistant genes carried by Enterobacterales that would modify the initial guideline-recommended antibiotics in every case. CMg was also 100% concordant with quantitative PCR for detecting Aspergillus fumigatus from 4 positive and 39 negative samples. Molecular typing using 24-h sequencing data identified an MDR-K. pneumoniae ST307 outbreak involving 4 patients and an MDR-C. striatum outbreak involving 14 patients across three ICUs.

Conclusion

CMg testing provides accurate pathogen detection and antibiotic resistance prediction in a same-day laboratory workflow, with assembled genomes available the next day for genomic surveillance. The provision of this technology in a service setting could fundamentally change the multi-disciplinary team approach to managing ICU infections. The potential to improve the initial targeted treatment and rapidly detect unsuspected outbreaks of MDR-pathogens justifies further expedited clinical assessment of CMg.

Details

Title
Evaluating the potential for respiratory metagenomics to improve treatment of secondary infection and detection of nosocomial transmission on expanded COVID-19 intensive care units
Author
Charalampous, Themoula  VIAFID ORCID Logo  ; Alcolea-Medina, Adela; Snell, Luke B; Williams, Tom G S; Batra, Rahul; Alder, Christopher; Telatin, Andrea; Camporota, Luigi; Meadows, Christopher I S; Duncan Wyncoll; Barrett, Nicholas A; Hemsley, Carolyn J; Bryan, Lisa; Newsholme, William; Boyd, Sara E; Green, Anna; Mahadeva, Ula; Patel, Amita; Cliff, Penelope R; Page, Andrew J; Justin O’Grady; Edgeworth, Jonathan D
Pages
1-16
Section
Research
Publication year
2021
Publication date
2021
Publisher
BioMed Central
e-ISSN
1756994X
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2599136190
Copyright
© 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.